PRINCETON, N.J. — Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, today announced the expansion of its BubbleGen™ cell selection portfolio with the launch of the BubbleGen CD3+ T Cell Selection Kit. The kit, built on Bracco’s microbubble technology, can enable new cell therapy workflows, including a highly scalable and cost-effective approach to manufacturing CAR-T cell therapies. This marks the first of multiple planned expansions of the BubbleGen family of cell selection solutions following the launch of its early access program in May this year. Read More